Results 251 to 260 of about 5,486,230 (294)
Some of the next articles are maybe not open access.
Current Treatment Options in Oncology, 2001
Ovarian cancer spreads early in the disease into the abdomen. An en bloc resection of the tumor, according to surgical principle, is not possible in patients with high-stage ovarian cancer. At surgery, large pelvic tumor lesions are found together with multiple tumor lesions involving the omentum, bowel, and mesentery together with a diffuse peritoneal
openaire +2 more sources
Ovarian cancer spreads early in the disease into the abdomen. An en bloc resection of the tumor, according to surgical principle, is not possible in patients with high-stage ovarian cancer. At surgery, large pelvic tumor lesions are found together with multiple tumor lesions involving the omentum, bowel, and mesentery together with a diffuse peritoneal
openaire +2 more sources
Treatment of advanced ovarian cancer
European Journal of Cancer, 2001Chemotherapy for advanced ovarian cancer has evolved over the past 25 years from the initial use of alkylating agents such as melphalan. Combinations containing cisplatin, cyclophosphamide and doxorubicin were studied in the 1980s and showed improved median progression-free survival.
openaire +2 more sources
Therapeutic advances in ovarian cancer
Current Opinion in Obstetrics and Gynecology, 1992The propensity of ovarian cancer to recur--even after initial chemotherapeutic responses--is a problem that has been given a great deal of attention during the past year in the literature dealing with the treatment of ovarian cancer. Most of the articles address techniques to improve the percent of initial and secondary treatment responses.
openaire +2 more sources
Treatment Advances in Ovarian Cancer
Cancer Nursing, 2003Ovarian cancer is the fifth leading cause of cancer death among women. Although many patients respond to initial surgery and platinum-based chemotherapy regimens, recurrence is common, and many individuals require treatment with multiple agents. A number of drugs not cross-reactive with platinums or taxanes are effective as secondary treatment for ...
openaire +2 more sources
Sarcopenia in Advanced Serous Ovarian Cancer
International Journal of Gynecological Cancer, 2017Cancer cachexia is a paraneoplastic syndrome comprising involuntary weight loss and muscle depletion (sarcopenia). Although weight loss has been associated with poor clinical outcome, there is only limited information on the prevalence and prognostic impact of sarcopenia in ovarian cancer so far.Total skeletal muscle mass was determined by computed ...
Holger, Bronger +6 more
openaire +2 more sources
Chemotherapeutic management of advanced ovarian cancer
Seminars in Oncology Nursing, 2003To review current treatment strategies for patients with advanced ovarian cancer. Factors for treatment selection are discussed.Research articles and textbooks.Research efforts continue to identify novel agents and/or combination therapies that can effect a cure or prolong survival.
Alan N, Gordon, Julie, Butler
openaire +2 more sources
Advances in the staging and treatment of ovarian cancer
Cancer, 1977The age adjusted death rate for ovarian cancer has remained unchanged for the past 20 years. Recent data obtained by staging ovarian cancer patients with lymphangiography and peritoneoscopy demonstrated that many patients with apparently localized disease actually have occult dissemination within the abdomen.
R I, Fisher, R C, Young
openaire +2 more sources
Surgical Management of Advanced Ovarian Cancer
Obstetrical & Gynecological Survey, 2000Surgery is an essential part of the management of patients presenting with ovarian cancer. Diagnosis, staging, and therapy can be carried out at the time of laparotomy. Unfortunately, the disease often presents at an advanced stage and the outlook for patients is poor with an overall 5-year survival rate of 23%.
D, Nunns, P, Symonds, D, Ireland
openaire +2 more sources
Surgery for advanced epithelial ovarian cancer
Best Practice & Research Clinical Obstetrics & Gynaecology, 2017Cytoreductive surgery for patients with advanced epithelial ovarian cancer has been practised since the pioneering work of Tom Griffiths in 1975. Further research has demonstrated the prognostic significance of the extent of metastatic disease pre-operatively, and of complete cytoreduction post-operatively.
Neville F, Hacker, Archana, Rao
openaire +2 more sources
BMJ clinical evidence, 2016
Ovarian cancer is the fourth most common cause of cancer deaths in the UK. The 5-year relative survival rate in the UK at diagnosis for women aged 15-39 years is nearly 70%. In comparison, it is only 12% for women diagnosed aged over 80 years.We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of ...
Sean, Kehoe, Jo, Morrison
openaire +1 more source
Ovarian cancer is the fourth most common cause of cancer deaths in the UK. The 5-year relative survival rate in the UK at diagnosis for women aged 15-39 years is nearly 70%. In comparison, it is only 12% for women diagnosed aged over 80 years.We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of ...
Sean, Kehoe, Jo, Morrison
openaire +1 more source